Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5699356 | Clinical Oncology | 2010 | 6 Pages |
Abstract
This modelling suggests a small therapeutic gain for the use of synchronous chemotherapy instead of radiotherapy dose escalation. This conclusion is dependent on the linear quadratic model and takes no account of late side-effects. This gain would be greater for agents that enhance the mucosal reaction to a lesser degree. This gain may be less when data for radiotherapy dose escalation to smaller high dose volumes using intensity-modulated radiotherapy are considered.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
A. Hartley, P. Sanghera, J. Glaholm, H. Mehanna, C. McConkey, J. Fowler,